Skip to content
Open access

EP377 - ECE_3691 - FABP4 and fatty liver index in obesity: insights across metabolic health categories

Aug 2026 · European Journal of Endocrinology · Vol 195 · 0 citations

TL;DR

The findings support FABP4 as a potential biomarker reflecting both metabolic phenotype and liver steatosis in obesity and further studies are needed to clarify the role of FABP4 as a non-invasive indicator of NAFDL.

Abstract

Fatty Acid Binding Protein 4 (FABP4) is an intracellular lipid-binding protein involved in the regulation of fatty acid transport, lipid signalling, and cholesterol homeostasis. Elevated circulating FABP4 levels have been proposed as a potential biomarker for the detection and progression of liver steatosis. It represents the initial stage of non-alcoholic fatty liver disease (NAFDL), a condition strongly linked to metabolic dysregulation. Moreover, metabolic syndrome (MetS) is frequently associated with the development and severity of liver steatosis. The goal of this study is to examine the association of FAB4 with liver steatosis in metabolic healthy obese (MHO), pre-metabolic syndrome(pre—MetS) and metabolic syndrome (MetS) patient. We conducted a cross-sectional study including 103 treatment-naive obese patients (body mass index, BMI ≥ 30 kg/m2). Participants were divided into three groups: MHO (n = 18), who did not meet any MetS criteria and were not using antihypertensive, glucose-lowering, or lipid-lowering medications; pre-MetS (n = 32), who met at least one MetS criterion (excluding waist circumference), but did not fulfil the full MetS definition; and MetS (n = 53). Multiple biochemical parameters were analysed. BMI and waist circumference (WC) were assessed. The fatty liver index (FLI) was calculated using a validated logistic regression formula. An FLI ≥ 60 was considered indicative of a high risk of liver steatosis. FABP4 levels differed significantly between the three groups (P < .001). Further analysis showed lower FABP4 in the MHO group compared with both METS (P = .001) and pre-METs (P = .032), while MetS and pre-METs did not differ (P = .354). FLI also differed significantly between groups (P < .001), with all pairwise comparisons showing significance. FLI was higher in the MetS group than in the other groups, and higher in the pre-MetS group than in the MHO group. FABP4 correlated with FLI (r = 0.430), GGTP (r = 0.264) and ALT (r = 0.212). In binary logistic regression, FABP4 was positively associated with liver steatosis (FLI ≥ 60) in both crude (P < .001; OR 42.530 95% Cl 6.12-295.58) and adjusted models (P < .001; OR 1.22, 95% CI 1.078-1.378). FABP4 levels were higher in patients with FLI ≥ 60 than in those with FLI < 60 (P < .001). Overall, our findings support FABP4 as a potential biomarker reflecting both metabolic phenotype and liver steatosis in obesity. Further studies are needed to clarify the role of FABP4 as a non-invasive indicator of NAFDL.

Read PDF

Similar papers

Open access Aug 2026

Evaluation of sirtuin 1 serum level and gene expression in patients with metabolic syndrome accompanied by metabolic dysfunction-associated steatotic liver disease

Metabolic syndrome is a cluster of conditions, including abdominal obesity, dyslipidemia, hypertension, and impaired glucose metabolism, that significantly increase the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM). Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently intro...

Fawzy A. El-Messallamy, Mayada M. Mousa, Ahmad Sallam Soliman et al. · 0 citations
Open access Aug 2026

Transcriptomic analysis identifies FABP5 as a candidate regulator of lipid accumulation in metabolic dysfunction-associated fatty liver disease

Hematic Fabp5 expression and circulating FABP5 concentrations are reduced in experimental and human MAFLD, suggesting that FABP5 is a candidate regulator of hepatic lipid metabolism and warrants further investigation as a potential therapeutic target.

Kai-Shuo Lv, Shu-Hang Zhong, Xiao-Qing Liu et al. · 0 citations
Open access Sep 2026

Transcriptomic Architecture of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Risk in Mexican Americans

Highlights What are the main findings? Hepatic steatosis (neutral lipid) measures in iPSC-derived hepatocyte cultures showed statistically significant additive genetic heritability at baseline (h2 = 0.44, p ≤ 0.05) and post-lipid challenge (h2 = 0.42, p ≤ 0.05). Transcriptome-wide association analysis identified 1070 g...

Satish Kumar, Miriam Aceves, Lorena Guerra et al. · 0 citations
Open access Sep 2026

C-peptide in MASLD – a potential driver of hepatic steatosis and fibrosis

It is proposed that C-peptide has evolved from a fibrosis biomarker to a mechanistic node and actionable target and routine integration into metabolic screening could enhance early risk stratification and monitoring of therapies modulating hyperinsulinemia.

Ahmed Mohammed Shennawy · 0 citations
Review Open access Sep 2026

The role of thyroid hormone beta 1 receptor (THRβ1) in metabolic dysfunction associated steatohepatitis (MASH): from dysregulation to therapeutic target.

The structure of THRβ1, how ligands bind to it, the mechanisms of its transcriptional regulation, and its roles in the metabolism of lipids, cholesterol, glucose, and mitochondria in the liver are reviewed, before going on to analyze the dysregulation of THRβ1 in MASH and the pharmacological and structural reasons for...

R. Patil, G. Viswanatha, Sai Balaji Andugulapati et al. · 1 citation
Open access Aug 2026

Targeting Circulating Fatty Acid Binding Protein 4 Ameliorates Obesity-Associated Hepatic Steatosis.

BACKGROUND & AIMS Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD), yet the molecular mechanisms linking excess adiposity to hepatocellular lipid accumulation remain incompletely defined. We investigated whether circulating fatty acid-binding protein 4 (FABP4) mediates adipo...

Xingshan Jiang, Anthony Avellino, Jianyu Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.